Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...

GREEN BAY, Wis. (WBAY) - Across our community, you’ll find unsung heroes giving of their time, talent and treasures to make Northeast Wisconsin a great place to live. WBAY is excited to begin a new ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...